Biofrontera (BFRI) vs BioVie (BIVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Biofrontera (BFRI) has outperformed BioVie (BIVI) over the past year, losing 28.4% versus a loss of 38.2%. Over five years, BFRI leads with a -99.7% price change compared with -99.9% for BIVI. Biofrontera is the larger company by market cap ($9.5 million vs $8.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BFRI | BIVI |
|---|---|---|
| Share price | $0.53 | $0.80 |
| Market cap | $9.51M | $8.58M |
| 1-day change | -7.02% | -12.07% |
| YTD return | -7.02% | -31.03% |
| 1-year return | -28.38% | -38.22% |
| 5-year return | -99.66% | -99.87% |
| Forward P/E | 1.32 | — |
| EPS (TTM) | $-0.26 | $-2.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $41.70M | — |
| Revenue growth (YoY) | +11.75% | — |
| Net income (latest FY) | $-10.54M | $-22.07M |
| Operating margin | -27.21% | — |
| Net margin | -25.26% | — |
| 52-week high | $1.66 | $3.79 |
| 52-week low | $0.53 | $0.7515 |
| Distance from 52-week high | -68.07% | -78.89% |
| Analyst consensus | none | none |
| Avg. price target upside | +1032.08% | +557.50% |
| Average volume | 429.04K | 568.61K |
| Shares outstanding | 17.95M | 10.72M |
| Employees | 84 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Biofrontera
BFRI stock →Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
About BioVie
BIVI stock →BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
BFRI vs BIVI FAQ
Which is bigger, Biofrontera or BioVie?
Biofrontera (BFRI) is larger, with a market capitalization of $9.51M compared with $8.58M for BioVie (BIVI).
Which stock has performed better over the past year, BFRI or BIVI?
BFRI returned -28.38% over the past 12 months, compared with -38.22% for BIVI (price return, excluding dividends). Past performance does not predict future results.
Are Biofrontera and BioVie in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.